跳至主要内容
临床试验/EUCTR2007-000306-70-GB
EUCTR2007-000306-70-GB进行中(未招募)1 期

The effect of metformin on biomarker activity in primary breast cancer - NeoMet Trial

niversity of Dundee0 个研究点目标入组 55 人开始时间: 2007年4月26日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
55

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • 1. Women able to comply with the protocol requirements with primary invasive breast cancer, histologically confirmed by core needle biopsy (see appendix 1: Preparation of core biopsies), with >30% positive malignant epithelial cells on histology, and identified = 1cm tumors on ultrasound and/ or mammography.
  • 2. Tumour measurable by clinical examination, mammography and ultrasound.
  • 3. Adequate bone marrow function as shown by: WBC =3.5 x 109/L, ANC =1.5 x 109/L, Platelets =100, Hb >10g/ dl
  • 4. Adequate liver function as shown by: serum bilirubin = 1.5 x ULN, albumin = 3g/dl, serum transaminases activity = 2.5 x ULN, alkaline phosphatase = 2.5 x ULN
  • 5. Normal renal function (serum creatinine = 1.5 x ULN, BUN 1.5 x ULN)
  • 6. A life expectancy of at least 6 months
  • 7. Written informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1. Any degree of renal impairment, measured by serum creatinine = 1.5 x ULN, BUN 1.5 x ULN
  • 2. Known diabetic patients
  • 4. Respiratory failure
  • 5. Liver failure
  • 6. Use of iodine-containing X-ray contrast media in the past 2 days.
  • 7. Patients likely to be considered to neo-adjuvant chemotherapy
  • 8. Patients who may require staging involving a contrast CT scan
  • 9. Patients with unstable angina, uncontrolled cardiac disease, or recent myocardial infarction (last 6 months)
  • 10. Evidence of distant metastasis
  • 11. Concomitant anti-cancer treatments such as chemotherapy, immunotherapy/ biological response modifiers (BRM’s), or radiotherapy.
  • 12. Other investigational drugs within the past 30 days or the concomitant use of investigational drugs,
  • 13. History of non-compliance to medical regimens and patients who are considered potentially unreliable
  • 14. Drugs in the same class, or likely to affect the LKB1/ AMPK/ mTOR pathway

研究者

发起方
niversity of Dundee

相似试验